{
    "clinical_study": {
        "@rank": "42120", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of E7070 in treating patients who have\n      stage IV melanoma."
        }, 
        "brief_title": "E7070 in Treating Patients With Stage IV Melanoma", 
        "condition": "Melanoma (Skin)", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Determine the therapeutic activity of E7070 in terms of objective response,\n      duration of response, and progression-free survival of patients with metastatic melanoma.\n      II. Determine the acute side effects of this drug in these patients. III. Determine the\n      pharmacokinetic parameters of this drug in these patients.\n\n      OUTLINE: This is a multicenter study. Patients receive E7070 IV over 1 hour. Treatment\n      repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.\n      Patients are followed every 6 weeks.\n\n      PROJECTED ACCRUAL: A total of 19-24 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Histologically confirmed stage IV melanoma Metastatic disease At\n        least 1 bidimensionally measurable target lesion by CT scan No brain metastases\n\n        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 OR WHO 0-2 Life\n        expectancy: Not specified Hematopoietic: Hemoglobin greater than 10 g/dL Neutrophil count\n        greater than 2,000/mm3 Platelet count greater than 100,000/mm3 Hepatic: Bilirubin less\n        than 1.5 times upper limit of normal (ULN) Alkaline phosphatase no greater than 2.5 times\n        ULN (5 times ULN if liver metastases present) Transaminases no greater than 2.5 times ULN\n        (5 times ULN if liver metastases present) Renal: Creatinine no greater than 1.7 mg/dL\n        Cardiovascular: Clinically normal cardiac function No history of severe or unstable\n        ischemic heart disease 12-lead ECG normal Other: No history of unstable systemic disease\n        No concurrent uncontrolled diabetes mellitus No concurrent infection No history of\n        hypersensitivity to sulfonamides No other malignancy within the past 5 years except\n        cone-biopsied carcinoma of the cervix or adequately treated basal cell or squamous cell\n        skin cancer No psychological, familial, sociological, or geographical condition that would\n        preclude study Not pregnant or nursing Negative pregnancy test Fertile patients must use\n        effective contraception\n\n        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 2 weeks since prior blood\n        transfusions At least 2 weeks since prior growth factors At least 6 weeks since prior\n        experimental vaccine therapy No prior immunotherapy for metastatic disease No concurrent\n        anticancer immunotherapy Chemotherapy: No prior chemotherapy for metastatic disease No\n        other concurrent anticancer chemotherapy Endocrine therapy: No concurrent anticancer\n        hormonal therapy Radiotherapy: No concurrent anticancer radiotherapy except palliation for\n        pain control or other reasons (e.g., bronchial obstruction or ulcerating skin lesions)\n        with no curative intent Surgery: Not specified Other: At least 6 weeks since prior\n        adjuvant or neoadjuvant therapy At least 4 weeks since prior experimental drugs At least 2\n        weeks since prior and no concurrent coumarin anti-coagulants, terfenadine, cisapride,\n        cyclosporine, tacrolimus, theophylline, diazepam, sulfonylurea anti-diabetics, phenytoin,\n        or carbamazepine No other concurrent experimental agents"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 10, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00014625", 
            "org_study_id": "EORTC-16005-18002", 
            "secondary_id": [
                "EORTC-16005", 
                "EORTC-18002", 
                "EISAI-E7070-E044-205"
            ]
        }, 
        "intervention": {
            "intervention_name": "indisulam", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "stage IV melanoma", 
            "recurrent melanoma"
        ], 
        "lastchanged_date": "July 23, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/EORTC-16005"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Vienna", 
                        "country": "Austria", 
                        "zip": "A-1100"
                    }, 
                    "name": "Kaiser Franz Josef Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1000"
                    }, 
                    "name": "Institut Jules Bordet"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clermont-Ferrand", 
                        "country": "France", 
                        "zip": "63011"
                    }, 
                    "name": "Centre Jean Perrin"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69373"
                    }, 
                    "name": "Centre Leon Berard"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France", 
                        "zip": "35064"
                    }, 
                    "name": "Centre Eugene Marquis"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hannover", 
                        "country": "Germany", 
                        "zip": "D-30625"
                    }, 
                    "name": "Medizinische Hochschule Hannover"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Naples", 
                        "country": "Italy", 
                        "zip": "80131"
                    }, 
                    "name": "Istituto Nazionale per lo Studio e la Cura dei Tumori"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oslo", 
                        "country": "Norway", 
                        "zip": "N-0310"
                    }, 
                    "name": "Norwegian Radium Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lisbon", 
                        "country": "Portugal", 
                        "zip": "1093"
                    }, 
                    "name": "Instituto Portugues de Oncologia de Francisco Gentil"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lausanne", 
                        "country": "Switzerland", 
                        "zip": "CH-1011"
                    }, 
                    "name": "Centre Hospitalier Universitaire Vaudois"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "state": "England", 
                        "zip": "SW3 6JJ"
                    }, 
                    "name": "Royal Marsden NHS Trust"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edinburgh", 
                        "country": "United Kingdom", 
                        "state": "Scotland", 
                        "zip": "EH4 2XU"
                    }, 
                    "name": "Western General Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Belgium", 
                "France", 
                "Germany", 
                "Italy", 
                "Norway", 
                "Portugal", 
                "Switzerland", 
                "United Kingdom"
            ]
        }, 
        "official_title": "Open Label Phase II Study Of E7070 In Patients With Metastatic Melanoma (Stage IV)", 
        "overall_official": [
            {
                "affiliation": "Edinburgh Cancer Centre at Western General Hospital", 
                "last_name": "John F. Smyth, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Norwegian Radium Hospital", 
                "last_name": "Steinar Aamdal, MD, PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2001", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00014625"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "15598954", 
            "citation": "Smyth JF, Aamdal S, Awada A, Dittrich C, Caponigro F, Schoffski P, Gore M, Lesimple T, Djurasinovic N, Baron B, Ravic M, Fumoleau P, Punt CJ; EORTC New Drug Development and Melanoma Groups. Phase II study of E7070 in patients with metastatic melanoma. Ann Oncol. 2005 Jan;16(1):158-61."
        }, 
        "source": "European Organisation for Research and Treatment of Cancer - EORTC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "European Organisation for Research and Treatment of Cancer - EORTC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2001", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }, 
    "geocoordinates": {
        "Centre Eugene Marquis": "48.113 -1.676", 
        "Centre Hospitalier Universitaire Vaudois": "46.52 6.634", 
        "Centre Jean Perrin": "45.777 3.087", 
        "Centre Leon Berard": "45.764 4.836", 
        "Institut Jules Bordet": "50.85 4.352", 
        "Instituto Portugues de Oncologia de Francisco Gentil": "38.707 -9.136", 
        "Istituto Nazionale per lo Studio e la Cura dei Tumori": "40.84 14.253", 
        "Kaiser Franz Josef Hospital": "48.208 16.374", 
        "Medizinische Hochschule Hannover": "52.384 9.727", 
        "Norwegian Radium Hospital": "59.914 10.752", 
        "Royal Marsden NHS Trust": "51.508 -0.128", 
        "Western General Hospital": "55.953 -3.188"
    }
}